Concepedia

Justin Ansell

JA

Statistics

Publications

12

Citations

573

H-Index

12

Active since

1981

Affiliations

Johnson & Johnson (United States)(Current)

Novartis (Switzerland)

Justin Ansell is an author at Johnson & Johnson (United States) specializing in pharmacology, life sciences, and enzyme inhibition.

Publications per year

1981–2011

12

Publications

12

Identification of protease 3.4.24.11 as the major atrial natriuretic factor degrading enzyme in the rat kidney

June L. Sonnenberg, Yumi Sakane, A. Y. Jeng et al. · Peptides · 1988 · 158 citations

, , +12

CGS 9343B, a novel, potent, and selective inhibitor of calmodulin activity.

Jon Norman, Justin Ansell, George A. Stone et al. · Molecular Pharmacology · 1987 · 109 citations

, , +12

Dihydropyridine Ca2+ entry blockers selectively inhibit peak I cAMP phosphodiesterase

Jon Norman, Justin Ansell, Mildred A. Phillipps · European Journal of Pharmacology · 1983 · 51 citations

, , +7

Synthesis and 5-Lipoxygenase Inhibitory Activities of Some Novel 2-Substituted 5-Benzofuran Hydroxamic Acids

Kwasi A. Ohemeng, Mary A. Appollina, Van N. Nguyen et al. · Journal of Medicinal Chemistry · 1994 · 45 citations · Full text

, , +10

N-Hydroxyurea and hydroxamic acid inhibitors of cyclooxygenase and 5-lipoxygenase

Peter J. Connolly, Steven K. Wetter, Kimberly N. Beers et al. · Bioorganic & Medicinal Chemistry Letters · 1999 · 43 citations · Full text

, , +8

1–5 of 12